Literature DB >> 17447260

Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635.

Eydie L Moses-Kolko1, Julie C Price, Michael E Thase, Carolyn Cidis Meltzer, David J Kupfer, Chester A Mathis, Wendy D Bogers, Susan R Berman, Patricia R Houck, Trisha N Schneider, Wayne C Drevets.   

Abstract

OBJECTIVE: To assess effects of chronic antidepressant drug treatment on serotonin type-1A receptor (5-HT(1A)R) binding potential (BP) in major depressive disorder.
METHODS: Depressed subjects (n = 27) were imaged using PET and [(11)C]WAY-100635 at baseline and following a median of 9.4 weeks of treatment with selective serotonin reuptake inhibitor or dual reuptake inhibitor antidepressant agents. Fifteen subjects had complete pre- and post-treatment scan data. The 5-HT(1A)R BP was derived from the tissue time-radioactivity concentrations from regions-of-interest defined a priori, using a simplified reference tissue model (SRTM), and in a subset of subjects, compartmental modeling (CMOD).
RESULTS: Chronic treatment had no effect on pre- or post-synaptic 5-HT(1A)R BP, as confirmed by both the SRTM and CMOD analyses. These results were unaffected by treatment response status and were consistent across brain regions. Among the 22 subjects for whom the clinical response-to-treatment was established, the treatment nonresponders (n = 7) had higher baseline BP values in the left (P = 0.01) and right orbital cortex (P = 0.02) than the responders (n = 15).
CONCLUSIONS: Chronic antidepressant drug treatment did not significantly change cerebral 5-HT(1A)R binding, consistent with preclinical evidence that the alterations in serotonergic function associated with antidepressant drug administration are not accompanied by changes in 5-HT(1A)R density. Higher baseline 5-HT(1A)R binding was associated with poorer response to treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17447260      PMCID: PMC4448112          DOI: 10.1002/syn.20398

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  41 in total

1.  Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study.

Authors:  Ramin V Parsey; Maria A Oquendo; R Todd Ogden; Doreen M Olvet; Norman Simpson; Yung-Yu Huang; Ronald L Van Heertum; Victoria Arango; J John Mann
Journal:  Biol Psychiatry       Date:  2005-09-09       Impact factor: 13.382

2.  Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims.

Authors:  V Arango; M D Underwood; M Boldrini; H Tamir; S A Kassir; S Hsiung; J J Chen; J J Mann
Journal:  Neuropsychopharmacology       Date:  2001-12       Impact factor: 7.853

3.  Evidence of the dual mechanisms of action of venlafaxine.

Authors:  A T Harvey; R L Rudolph; S H Preskorn
Journal:  Arch Gen Psychiatry       Date:  2000-05

4.  PET imaging of serotonin 1A receptor binding in depression.

Authors:  W C Drevets; E Frank; J C Price; D J Kupfer; D Holt; P J Greer; Y Huang; C Gautier; C Mathis
Journal:  Biol Psychiatry       Date:  1999-11-15       Impact factor: 13.382

5.  Evidence of increased serotonin-1A receptor binding in type 2 diabetes: a positron emission tomography study.

Authors:  Julie C Price; David E Kelley; Christopher M Ryan; Carolyn C Meltzer; Wayne C Drevets; Chester A Mathis; Sati Mazumdar; Charles F Reynolds
Journal:  Brain Res       Date:  2002-02-08       Impact factor: 3.252

6.  Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat.

Authors:  J Béïque; C de Montigny; P Blier; G Debonnel
Journal:  Neuropharmacology       Date:  2000-07-24       Impact factor: 5.250

7.  Serotonin 1A receptor binding and treatment response in late-life depression.

Authors:  Carolyn Cidis Meltzer; Julie C Price; Chester A Mathis; Meryl A Butters; Scott K Ziolko; Eydie Moses-Kolko; Sati Mazumdar; Benoit H Mulsant; Patricia R Houck; Brian J Lopresti; Lisa A Weissfeld; Charles F Reynolds
Journal:  Neuropsychopharmacology       Date:  2004-12       Impact factor: 7.853

8.  A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans.

Authors:  Sean P David; Naga Venkatesha Murthy; Eugenii A Rabiner; Marcus R Munafó; Elaine C Johnstone; Robyn Jacob; Robert T Walton; Paul M Grasby
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

9.  [3H]8-OH-DPAT binding and serotonin content in rat cerebral cortex after acute fluoxetine, desipramine, or pargyline.

Authors:  M Carli; S Afkhami-Dastjerdian; T A Reader
Journal:  J Psychiatry Neurosci       Date:  1996-03       Impact factor: 6.186

Review 10.  Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration.

Authors:  Julie G Hensler
Journal:  Life Sci       Date:  2003-02-28       Impact factor: 5.037

View more
  20 in total

1.  Human Freud-2/CC2D1B: a novel repressor of postsynaptic serotonin-1A receptor expression.

Authors:  Mahmoud R Hadjighassem; Mark C Austin; Bernadeta Szewczyk; Mireille Daigle; Craig A Stockmeier; Paul R Albert
Journal:  Biol Psychiatry       Date:  2009-05-07       Impact factor: 13.382

2.  Monoamine oxidase A genotype predicts human serotonin 1A receptor availability in vivo.

Authors:  Brian J Mickey; Francesca Ducci; Colin A Hodgkinson; Scott A Langenecker; David Goldman; Jon-Kar Zubieta
Journal:  J Neurosci       Date:  2008-10-29       Impact factor: 6.167

3.  Oestradiol alters central 5-HT1A receptor binding potential differences related to psychosocial stress but not differences related to 5-HTTLPR genotype in female rhesus monkeys.

Authors:  V Michopoulos; M Perez Diaz; M Embree; K Reding; J R Votaw; J Mun; R J Voll; M M Goodman; M Wilson; M Sanchez; D Toufexis
Journal:  J Neuroendocrinol       Date:  2014-02       Impact factor: 3.627

Review 4.  Positron emission tomography molecular imaging in late-life depression.

Authors:  Kentaro Hirao; Gwenn S Smith
Journal:  J Geriatr Psychiatry Neurol       Date:  2014-01-05       Impact factor: 2.680

5.  The molecular background of sex difference in depressive disorders: still an enigma.

Authors:  Alexander Becherer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12       Impact factor: 9.236

6.  Reduced post-synaptic serotonin type 1A receptor binding in bipolar depression.

Authors:  Allison C Nugent; Earle E Bain; Paul J Carlson; Alexander Neumeister; Omer Bonne; Richard E Carson; William Eckelman; Peter Herscovitch; Carlos A Zarate; Dennis S Charney; Wayne C Drevets
Journal:  Eur Neuropsychopharmacol       Date:  2013-02-20       Impact factor: 4.600

Review 7.  Stress and the reproductive axis.

Authors:  D Toufexis; M A Rivarola; H Lara; V Viau
Journal:  J Neuroendocrinol       Date:  2014-09       Impact factor: 3.627

Review 8.  Molecular imaging in patients with mood disorders: a review of PET findings.

Authors:  Qiaozhen Chen; Weibo Liu; Huichun Li; Hong Zhang; Mei Tian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

9.  Comorbidity between temporal lobe epilepsy and depression: a [18F]MPPF PET study.

Authors:  A Lothe; A Didelot; A Hammers; N Costes; M Saoud; F Gilliam; P Ryvlin
Journal:  Brain       Date:  2008-09-02       Impact factor: 13.501

10.  Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality.

Authors:  Jeffrey M Miller; Kathleen G Brennan; Todd R Ogden; Maria A Oquendo; Gregory M Sullivan; J John Mann; Ramin V Parsey
Journal:  Neuropsychopharmacology       Date:  2009-05-20       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.